{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:26:38Z","timestamp":1791264398265,"version":"4.1.0"},"reference-count":82,"publisher":"Oxford University Press (OUP)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,10,1]]},"DOI":"10.1093\/glycob\/cwi076","type":"journal-article","created":{"date-parts":[[2005,5,19]],"date-time":"2005-05-19T00:43:58Z","timestamp":1116463438000},"page":"43R-52R","source":"Crossref","is-referenced-by-count":195,"title":["Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses"],"prefix":"10.1093","volume":"15","author":[{"given":"Terry D.","family":"Butters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond A.","family":"Dwek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances M.","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,5,18]]},"reference":[{"key":"key\n\t\t\t\t20171012163544_ABE-ET-AL-2000","doi-asserted-by":"crossref","unstructured":"Abe, A. , Gregory, S., Lee, L., Killen, P.D., Brady, R.O., Kulkarni, A., and Shayman, J.A. (2000) Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J. Clin. Invest, 105, 1563\u20131571.","DOI":"10.1172\/JCI9711"},{"key":"key\n\t\t\t\t20171012163544_ALLENDE-AND-PROIA-2002","doi-asserted-by":"crossref","unstructured":"Allende, M.L. and Proia, R.L. (2002) Lubricating cell signalling pathways with gangliosides. Curr. Opin. Struct. Biol.,12, 587\u2013592.","DOI":"10.1016\/S0959-440X(02)00376-7"},{"key":"key\n\t\t\t\t20171012163544_ANDERSSON-ET-AL-2000","doi-asserted-by":"crossref","unstructured":"Andersson, U. , Butters, T.D., Dwek, R.A., and Platt, F.M. (2000) N-Butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem. Pharmacol.,59, 821\u2013829.","DOI":"10.1016\/S0006-2952(99)00384-6"},{"key":"key\n\t\t\t\t20171012163544_ANDERSSON-ET-AL-2004","doi-asserted-by":"crossref","unstructured":"Andersson, U. , Smith, D., Jeyakumar, M., Butters, T.D., Borja, M.C., Dwek, R.A., and Platt, F.M. (2004) Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease. Neurobiol. Dis.,16, 506\u2013515.","DOI":"10.1016\/j.nbd.2004.04.012"},{"key":"key\n\t\t\t\t20171012163544_ASANO-ET-AL-2000","doi-asserted-by":"crossref","unstructured":"Asano, N. , Ishii, S., Kizu, H., Ikeda, K., Yasuda, K., Kato, A., Martin, O.R., and Fan, J.Q. (2000) In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur. J. Biochem.,267, 4179\u20134186.","DOI":"10.1046\/j.1432-1327.2000.01457.x"},{"key":"key\n\t\t\t\t20171012163544_BLOCK-ET-AL-1998","doi-asserted-by":"crossref","unstructured":"Block, T.M. , Lu, X.Y., Mehta, A.S., Blumberg, B.S., Tennant, B., Ebling, M., Korba, B., Lansky, D.M., Jacob, G.S., and Dwek, R.A. (1998) Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat. Med.,4, 610\u2013614.","DOI":"10.1038\/nm0598-610"},{"key":"key\n\t\t\t\t20171012163544_BOUCHERON-ET-AL-2005","doi-asserted-by":"crossref","unstructured":"Boucheron, C. , Desvergnes, V., Compain, P., Martin, O.R., Lavi, A., Mackeen, M., Wormald, M.R., Dwek, R.A., and Butters, T.D. (2005) Design and synthesis of iminosugar-based inhibitors of glucosylceramide synthase: the search for new therapeutic agents against Gaucher disease. Tetrahedron Asymmetry, 16, 1747\u20131756.","DOI":"10.1016\/j.tetasy.2005.03.015"},{"key":"key\n\t\t\t\t20171012163544_BRADY-2003","doi-asserted-by":"crossref","unstructured":"Brady, R.O. (2003) Enzyme replacement therapy: conception, chaos and culmination. Philos. Trans. R. Soc. Lond. B. Biol. Sci.,358, 915\u2013919.","DOI":"10.1098\/rstb.2003.1269"},{"key":"key\n\t\t\t\t20171012163544_BUTTERS-ET-AL-2000A","doi-asserted-by":"crossref","unstructured":"Butters, T.D. , Dwek, R.A., and Platt, F.M. (2000) Inhibition of glycosphingolipid biosynthesis: application to lysosomal storage disorders. Chem. Rev.,100, 4683\u20134696.","DOI":"10.1021\/cr990292q"},{"key":"key\n\t\t\t\t20171012163544_BUTTERS-ET-AL-2000B","doi-asserted-by":"crossref","unstructured":"Butters, T.D. , van den Broek, L.A.G.M., Fleet, G.W.J., Krulle, T.M., Wormald, M.R., Dwek, R.A., and Platt, F.M. (2000) Molecular requirements of imino sugars for the selective control of N-linked glycosylation and glycosphingolipid biosynthesis. Tetrahedron Asymmetry, 11, 113\u2013124.","DOI":"10.1016\/S0957-4166(99)00468-1"},{"key":"key\n\t\t\t\t20171012163544_BUTTERS-ET-AL-2003A","doi-asserted-by":"crossref","unstructured":"Butters, T.D. , Dwek, R.A., and Platt, F.M. (2003) New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases. Adv. Exp. Med. Biol.,535, 219\u2013226.","DOI":"10.1007\/978-1-4615-0065-0_14"},{"key":"key\n\t\t\t\t20171012163544_BUTTERS-ET-AL-2003B","doi-asserted-by":"crossref","unstructured":"Butters, T.D. , Dwek, R.A., and Platt, F.M. (2003) Therapeutic applications of imino sugars in lysosomal storage disorders. Curr. Top. Med. Chem.,3, 561\u2013574.","DOI":"10.2174\/1568026033452483"},{"key":"key\n\t\t\t\t20171012163544_BUTTERS-ET-AL-2003C","doi-asserted-by":"crossref","unstructured":"Butters, T.D. , Mellor, H.R., Narita, K., Dwek, R.A., and Platt, F.M. (2003) Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders. Philos. Trans. R. Soc. Lond. B Biol. Sci.,358, 927\u2013945.","DOI":"10.1098\/rstb.2003.1278"},{"key":"key\n\t\t\t\t20171012163544_COX-ET-AL-2000","doi-asserted-by":"crossref","unstructured":"Cox, T. , Lachmann, R., Hollak, C., Aerts, J., van Weely, S., Hrebicek, M., Platt, F., Butters, T., Dwek, R., Moyses, C., and others. (2000) Novel oral treatment of Gaucher\u2019s disease with N-butyldeoxynojirimycin (OGT, 918) to decrease substrate biosynthesis. Lancet, 355, 1481\u20131485.","DOI":"10.1016\/S0140-6736(00)02161-9"},{"key":"key\n\t\t\t\t20171012163544_DESNICK-ET-AL-2001","unstructured":"Desnick, R.J. , Ioannou, Y.A., and Eng, C.M. (2001) a-Galactosidase A deficiency: Fabry disease. In The Metabolic & Moleculer Bases of Inherited Disease. McGraw-Hill, New York, 3, 3733\u20133774."},{"key":"key\n\t\t\t\t20171012163544_DESNICK-AND-SCHUCHMAN-2002","doi-asserted-by":"crossref","unstructured":"Desnick, R.J. and Schuchman, E.H. (2002) Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat. Rev. Genet.,3, 954\u2013966.","DOI":"10.1038\/nrg963"},{"key":"key\n\t\t\t\t20171012163544_DWEK-ET-AL-2002","doi-asserted-by":"crossref","unstructured":"Dwek, R.A. , Butters, T.D., Platt, F.M., and Zitzmann, N. (2002) Targeting glycosylation as a therapeutic approach. Nat. Rev. Drug Discov.,1, 65\u201375.","DOI":"10.1038\/nrd708"},{"key":"key\n\t\t\t\t20171012163544_ECKFORD-AND-SHAROM-2005","doi-asserted-by":"crossref","unstructured":"Eckford, P.D.W. and Sharom, F.J. (2005) The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. Biochem. J. Epub ahead of print.","DOI":"10.1042\/BJ20050047"},{"key":"key\n\t\t\t\t20171012163544_ELBEIN-1991","doi-asserted-by":"crossref","unstructured":"Elbein, A.D. (1991) Glycosidase inhibitors: inhibitors of N-linked oligosaccharide processing. FASEB J.,5, 3055\u20133063.","DOI":"10.1096\/fasebj.5.15.1743438"},{"key":"key\n\t\t\t\t20171012163544_ELSTEIN-ET-AL-2004","doi-asserted-by":"crossref","unstructured":"Elstein, D. , Hollak, C., Aerts, J.M., van Weely, S., Maas, M., Cox, T.M., Lachmann, R.H., Hrebicek, M., Platt, F.M., Butters, T.D., and others. (2004) Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT, 918) in type I Gaucher disease. J. Inherit Metab. Dis.,27, 757\u2013766.","DOI":"10.1023\/B:BOLI.0000045756.54006.17"},{"key":"key\n\t\t\t\t20171012163544_FAN-2003","doi-asserted-by":"crossref","unstructured":"Fan, J.Q. (2003) A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharmacol. Sci.,24, 355\u2013360.","DOI":"10.1016\/S0165-6147(03)00158-5"},{"key":"key\n\t\t\t\t20171012163544_FAN-ET-AL-1999","doi-asserted-by":"crossref","unstructured":"Fan, J.Q. , Ishii, S., Asano, N., and Suzuki, Y. (1999) Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat. Med.,5, 112\u2013115.","DOI":"10.1038\/4801"},{"key":"key\n\t\t\t\t20171012163544_FISCHER-ET-AL-1995","doi-asserted-by":"crossref","unstructured":"Fischer, P.B. , Collin, M., Karlsson, G.B., James, W., Butters, T.D., Davis, S.J., Gordon, S., Dwek, R.A., and Platt, F.M. (1995) The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding. J. Virol.,69, 5791\u20135797.","DOI":"10.1128\/JVI.69.9.5791-5797.1995"},{"key":"key\n\t\t\t\t20171012163544_FISCHER-ET-AL-1996","doi-asserted-by":"crossref","unstructured":"Fischer, P.B. , Karlsson, G.B., Butters, T.D., Dwek, R.A., and Platt, F.M. (1996) N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1\/V2 region of gp120. J. Virol.,70, 7143\u20137152.","DOI":"10.1128\/JVI.70.10.7143-7152.1996"},{"key":"key\n\t\t\t\t20171012163544_FISCHL-ET-AL-1994","unstructured":"Fischl, M.A. , Resnick, L., Coombs, R., Kremer, A.B., Pottage, Jr., J.C., Fass, R.J., Fife, K.H., Powderly, W.J., Collier, A.C., Aspinall, R.L., and others. (1994) The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200\u2013500 CD4 cells\/mm3. J. Acquir. Immune Defic. Syndr.,7, 139\u2013147."},{"key":"key\n\t\t\t\t20171012163544_FUJITA-ET-AL-1996","doi-asserted-by":"crossref","unstructured":"Fujita, N. , Suzuki, K., Vanier, M.T., Popko, B., Maeda, N., Klein, A., Henseler, M., Sandhoff, K., and Nakayasu, H. (1996) Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Hum. Mol. Genet, 5, 711\u2013725.","DOI":"10.1093\/hmg\/5.6.711"},{"key":"key\n\t\t\t\t20171012163544_FURST-AND-SANDHOFF-1992","doi-asserted-by":"crossref","unstructured":"Furst, W. and Sandhoff, K. (1992) Activator proteins and topology of lysosomal sphingolipid catabolism. Biochim. Biophys. Acta, 1126, 1\u201316.","DOI":"10.1016\/0005-2760(92)90210-M"},{"key":"key\n\t\t\t\t20171012163544_HEITNER-ET-AL-2002","doi-asserted-by":"crossref","unstructured":"Heitner, R. , Elstein, D., Aerts, J., van Weely, S., and Zimran, A. (2002) Low-dose N-butyldeoxynojirimycin (OGT918) for type I Gaucher disease. Blood Cells Mol. Dis.,28, 127\u2013133.","DOI":"10.1006\/bcmd.2002.0497"},{"key":"key\n\t\t\t\t20171012163544_HELENIUS-AND-AEBI-2001","doi-asserted-by":"crossref","unstructured":"Helenius, A. and Aebi, M. (2001) Intracellular functions of N-linked glycans. Science, 291, 2364\u20132369.","DOI":"10.1126\/science.291.5512.2364"},{"key":"key\n\t\t\t\t20171012163544_ISHII-ET-AL-2004","doi-asserted-by":"crossref","unstructured":"Ishii, S. , Yoshioka, H., Mannen, K., Kulkarni, A.B., and Fan, J.Q. (2004) Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease. Biochim. Biophys. Acta, 1690, 250\u2013257.","DOI":"10.1016\/j.bbadis.2004.07.001"},{"key":"key\n\t\t\t\t20171012163544_JEYAKUMAR-ET-AL-1999","doi-asserted-by":"crossref","unstructured":"Jeyakumar, M. , Butters, T.D., Cortina-Borja, M., Hunnam, V., Proia, R.L., Perry, V.H., Dwek, R.A., and Platt, F.M. (1999) Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc. Natl. Acad. Sci. U. S. A.,96, 6388\u20136393.","DOI":"10.1073\/pnas.96.11.6388"},{"key":"key\n\t\t\t\t20171012163544_JEYAKUMAR-ET-AL-2002","doi-asserted-by":"crossref","unstructured":"Jeyakumar, M. , Butters, T.D., Dwek, R.A., and Platt, F.M. (2002) Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis. Neuropathol. Appl. Neurobiol.,28, 343\u2013357.","DOI":"10.1046\/j.1365-2990.2002.00422.x"},{"key":"key\n\t\t\t\t20171012163544_JEYAKUMAR-ET-AL-2004","doi-asserted-by":"crossref","unstructured":"Jeyakumar, M. , Smith, D.A., Williams, I.M., Borja, M.C., Neville, D.C., Butters, T.D., Dwek, R.A., and Platt, F.M. (2004) NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. Ann. Neurol.,56, 642\u2013649.","DOI":"10.1002\/ana.20242"},{"key":"key\n\t\t\t\t20171012163544_JEYAKUMAR-ET-AL-2003","doi-asserted-by":"crossref","unstructured":"Jeyakumar, M. , Thomas, R., Elliot-Smith, E., Smith, D.A., van der Spoel, A.C., d\u2019Azzo, A., Perry, V.H., Butters, T.D., Dwek, R.A., and Platt, F.M. (2003) Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain, 126, 974\u2013987.","DOI":"10.1093\/brain\/awg089"},{"key":"key\n\t\t\t\t20171012163544_KOLTER-AND-SANDHOFF-1998","doi-asserted-by":"crossref","unstructured":"Kolter, T. and Sandhoff, K. (1998) Recent advances in the biochemistry of sphingolipidoses. Brain Pathol.,8, 79\u2013100.","DOI":"10.1111\/j.1750-3639.1998.tb00138.x"},{"key":"key\n\t\t\t\t20171012163544_KOLTER-AND-SANDHOFF-1999","doi-asserted-by":"crossref","unstructured":"Kolter, T. and Sandhoff, K. (1999) Sphingolipids \u2013 their metabolic pathways and the pathobiochemistry of neurodegenerative diseases. Angew. Chem. Intl. Ed.,38, 1532\u20131568.","DOI":"10.1002\/(SICI)1521-3773(19990601)38:11<1532::AID-ANIE1532>3.0.CO;2-U"},{"key":"key\n\t\t\t\t20171012163544_LACHMANN-ET-AL-2004","doi-asserted-by":"crossref","unstructured":"Lachmann, R.H. , Te Vruchte, D., Lloyd-Evans, E., Reinkensmeier, G., Sillence, D.J., Fernandez-Guillen, L., Dwek, R.A., Butters, T.D., Cox, T.M., and Platt, F.M. (2004) Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C. Neurobiol. Dis.,16, 654\u2013658.","DOI":"10.1016\/j.nbd.2004.05.002"},{"key":"key\n\t\t\t\t20171012163544_LEE-ET-AL-1999","doi-asserted-by":"crossref","unstructured":"Lee, L. , Abe, A., and Shayman, J.A. (1999) Improved inhibitors of glucosylceramide synthase. J. Biol. Chem.,274, 14662\u201314669.","DOI":"10.1074\/jbc.274.21.14662"},{"key":"key\n\t\t\t\t20171012163544_LEGLER-AND-POHL-1986","doi-asserted-by":"crossref","unstructured":"Legler, G. and Pohl, S. (1986) Synthesis of 5-amino-5-deoxy-D-galactopyranose and 1,5-dideoxy-1,5-imino-D-galactitol, and their inhibition of alpha- and beta-D-galactosidases. Carbohydr. Res.,155, 119\u2013129.","DOI":"10.1016\/S0008-6215(00)90138-1"},{"key":"key\n\t\t\t\t20171012163544_LIU-ET-AL-1997","doi-asserted-by":"crossref","unstructured":"Liu, Y. , Hoffmann, A., Grinberg, A., Westphal, H., McDonald, M.P., Miller, K.M., Crawley, J.N., Sandhoff, K., Suzuki, K., and Proia, R.L. (1997) Mouse model of GM2 activator deficiency manifests cerebellar pathology and motor impairment. Proc. Natl. Acad. Sci. U. S. A.,94, 8138\u20138143.","DOI":"10.1073\/pnas.94.15.8138"},{"key":"key\n\t\t\t\t20171012163544_LIU-ET-AL-1999","doi-asserted-by":"crossref","unstructured":"Liu, Y.J. , Wada, R., Kawai, H., Sango, K., Deng, C.X., Tai, T., McDonald, M.P., Araujo, K., Crawley, J.N., Bierfreund, U., and others. (1999) A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder. J. Clin. Invest, 103, 497\u2013505.","DOI":"10.1172\/JCI5542"},{"key":"key\n\t\t\t\t20171012163544_MEIKLE-ET-AL-1999","doi-asserted-by":"crossref","unstructured":"Meikle, P.J. , Hopwood, J.J., Clague, A.E., and Carey, W.F. (1999) Prevalence of lysosomal storage disorders. J. Am. Med. Assoc.,281, 249\u2013254.","DOI":"10.1001\/jama.281.3.249"},{"key":"key\n\t\t\t\t20171012163544_MELLOR-ET-AL-2004A","doi-asserted-by":"crossref","unstructured":"Mellor, H.R. , Neville, D.C., Harvey, D.J., Platt, F.M., Dwek, R.A., and Butters, T.D. (2004) Cellular effects of deoxynojirimycin analogues: inhibition of N-linked oligosaccharide processing and generation of free glucosylated oligosaccharides. Biochem. J.,381, 867\u2013875.","DOI":"10.1042\/BJ20031824"},{"key":"key\n\t\t\t\t20171012163544_MELLOR-ET-AL-2004B","doi-asserted-by":"crossref","unstructured":"Mellor, H.R. , Neville, D.C., Harvey, D.J., Platt, F.M., Dwek, R.A., and Butters, T.D. (2004) Cellular effects of deoxynojirimycin analogues: uptake, retention and inhibition of glycosphingolipid biosynthesis. Biochem. J.,381, 861\u2013866.","DOI":"10.1042\/BJ20031822"},{"key":"key\n\t\t\t\t20171012163544_MELLOR-ET-AL-2002","doi-asserted-by":"crossref","unstructured":"Mellor, H.R. , Nolan, J., Pickering, L., Wormald, M.R., Platt, F.M., Dwek, R.A., Fleet, G.W., and Butters, T.D. (2002) Preparation, biochemical characterization and biological properties of radiolabelled N\u2010alkylated deoxynojirimycins. Biochem. J.,366, 225\u2013233.","DOI":"10.1042\/bj20020466"},{"key":"key\n\t\t\t\t20171012163544_MELLOR-ET-AL-2003","doi-asserted-by":"crossref","unstructured":"Mellor, H.R. , Platt, F.M., Dwek, R.A., and Butters, T.D. (2003) Membrane disruption and cytotoxicity of hydrophobic N-alkylated imino sugars is independent of the inhibition of protein and lipid glycosylation. Biochem. J.,374, 307\u2013314.","DOI":"10.1042\/bj20030348"},{"key":"key\n\t\t\t\t20171012163544_MIZUKAMI-ET-AL-2002","doi-asserted-by":"crossref","unstructured":"Mizukami, H. , Mi, Y., Wada, R., Kono, M., Yamashita, T., Liu, Y., Werth, N., Sandhoff, R., Sandhoff, K., and Proia, R.L. (2002) Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. J. Clin. Invest, 109, 1215\u20131221.","DOI":"10.1172\/JCI0214530"},{"key":"key\n\t\t\t\t20171012163544_MORJANI-ET-AL-2001","doi-asserted-by":"crossref","unstructured":"Morjani, H. , Aouali, N., Belhoussine, R., Veldman, R.J., Levade, T., and Manfait, M. (2001) Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets. Int. J. Cancer, 94, 157\u2013165.","DOI":"10.1002\/ijc.1449"},{"key":"key\n\t\t\t\t20171012163544_NORFLUS-ET-AL-1998","doi-asserted-by":"crossref","unstructured":"Norflus, F. , Tifft, C.J., McDonald, M.P., Goldstein, G., Crawley, J.N., Hoffmann, A., Sandhoff, K., Suzuki, K., and Proia, R.L. (1998) Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice. J. Clin. Invest, 101, 1881\u20131888.","DOI":"10.1172\/JCI2127"},{"key":"key\n\t\t\t\t20171012163544_NORRIS-CERVETTO-ET-AL-2004","doi-asserted-by":"crossref","unstructured":"Norris-Cervetto, E. , Callaghan, R., Platt, F.M., Dwek, R.A., and Butters, T.D. (2004) Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells. J. Biol. Chem.,279, 40412\u201340418.","DOI":"10.1074\/jbc.M404466200"},{"key":"key\n\t\t\t\t20171012163544_PASTORES-AND-BARNETT-2003","doi-asserted-by":"crossref","unstructured":"Pastores, G.M. and Barnett, N.L. (2003) Substrate reduction therapy: miglustat as a remedy for symptomatic patients with Gaucher disease type 1. Expert Opin. Investig. Drugs, 12, 273\u2013281.","DOI":"10.1517\/13543784.12.2.273"},{"key":"key\n\t\t\t\t20171012163544_PLATT-AND-BUTTERS-1998","unstructured":"Platt, F.M. and Butters, T.D. (1998) New therapeutic prospects for the glycosphingolipid lysosomal storage diseases. Biochem. Pharmacol.,56, 421\u2013430."},{"key":"key\n\t\t\t\t20171012163544_PLATT-ET-AL-2003","doi-asserted-by":"crossref","unstructured":"Platt, F.M. , Jeyakumar, M., Andersson, U., Heare, T., Dwek, R.A., and Butters, T.D. (2003) Substrate reduction therapy in mouse models of the glycosphingolipidoses. Philos. Trans. R. Soc. Lond. B Biol. Sci.,358, 947\u2013954.","DOI":"10.1098\/rstb.2003.1279"},{"key":"key\n\t\t\t\t20171012163544_PLATT-ET-AL-1994A","doi-asserted-by":"crossref","unstructured":"Platt, F.M. , Neises, G.R., Dwek, R.A., and Butters, T.D. (1994) N-Butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J. Biol. Chem.,269, 8362\u20138365.","DOI":"10.1016\/S0021-9258(17)37202-2"},{"key":"key\n\t\t\t\t20171012163544_PLATT-ET-AL-1994B","doi-asserted-by":"crossref","unstructured":"Platt, F.M. , Neises, G.R., Karlsson, G.B., Dwek, R.A., and Butters, T.D. (1994) N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. J. Biol. Chem.,269, 27108\u201327114.","DOI":"10.1016\/S0021-9258(18)47132-3"},{"key":"key\n\t\t\t\t20171012163544_PLATT-ET-AL-1997","doi-asserted-by":"crossref","unstructured":"Platt, F.M. , Neises, G.R., Reinkensmeier, G., Townsend, M.J., Perry, V.H., Proia, R.L., Winchester, B., Dwek, R.A., and Butters, T.D. (1997) Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science, 276, 428\u2013431.","DOI":"10.1126\/science.276.5311.428"},{"key":"key\n\t\t\t\t20171012163544_PLATT-AND-WALKLEY-2004","doi-asserted-by":"crossref","unstructured":"Platt, F.M. and Walkley, S.U. (2004) Lysosomal Disorders of the Brain. Oxford University Press, Oxford.","DOI":"10.1093\/acprof:oso\/9780198508786.001.0001"},{"key":"key\n\t\t\t\t20171012163544_PREMKUMAR-ET-AL-2005","doi-asserted-by":"crossref","unstructured":"Premkumar, L. , Sawkar, A.R., Boldin-Adamsky, S., Toker, L., Silman, I., Kelly, J.W., Futerman, A.H., and Sussman, J.L. (2005) X-ray structure of human acid \u03b2-glucosidase covalently-bound to conduritol-\u03b2-epoxide: implications for Gaucher disease. J. Biol. Chem. Epub ahead of print.","DOI":"10.2210\/pdb1y7v\/pdb"},{"key":"key\n\t\t\t\t20171012163544_PRIESTMAN-ET-AL-2000","unstructured":"Priestman, D.A. , Platt, F.M., Dwek, R.A., and Butters, T.D. (2000) Imino sugar therapy for type I Gaucher disease. Glycobiology, 19, iv\u2013vi."},{"key":"key\n\t\t\t\t20171012163544_PROIA-2003","doi-asserted-by":"crossref","unstructured":"Proia, R.L. (2003) Glycosphingolipid functions: insights from engineered mouse models. Philos. Trans. R. Soc. Lond. B. Biol. Sci.,358, 879\u2013883.","DOI":"10.1098\/rstb.2003.1268"},{"key":"key\n\t\t\t\t20171012163544_RADIN-1996","doi-asserted-by":"crossref","unstructured":"Radin, N.S. (1996) Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj. J.,13, 153\u2013157.","DOI":"10.1007\/BF00731489"},{"key":"key\n\t\t\t\t20171012163544_RADIN-2003","doi-asserted-by":"crossref","unstructured":"Radin, N.S. (2003) Killing tumours by ceramide-induced apoptosis: a critique of available drugs. Biochem. J.,371, 243\u2013256.","DOI":"10.1042\/bj20021878"},{"key":"key\n\t\t\t\t20171012163544_RAGGERS-ET-AL-2000","doi-asserted-by":"crossref","unstructured":"Raggers, R.J. , Pomorski, T., Holthuis, J.C., Kalin, N., and van Meer, G. (2000) Lipid traffic: the ABC of transbilayer movement. Traffic, 1, 226\u2013234.","DOI":"10.1034\/j.1600-0854.2000.010305.x"},{"key":"key\n\t\t\t\t20171012163544_SALVIOLI-ET-AL-2005","doi-asserted-by":"crossref","unstructured":"Salvioli, R. , Tatti, M., Scarpa, S., Moavero, S.M., Ciaffoni, F., Felicetti, F., Kaneski, C.R., Brady, R.O., and Vaccaro, A.M. (2005) The N370S mutation affects the capacity of glucosylceramidase to interact with anionic phospholipid-containing membranes and Saposin C. Biochem. J. Epub ahead of print.","DOI":"10.1042\/BJ20050325"},{"key":"key\n\t\t\t\t20171012163544_SANO-ET-AL-2005","doi-asserted-by":"crossref","unstructured":"Sano, R. , Trindade, V.M., Tessitore, A., d\u2019Azzo, A., Vieira, M.B., Giugliani, R., and Coelho, J.C. (2005) G (M1) -ganglioside degradation and biosynthesis in human and murine G (M1) -gangliosidosis. Clin. Chim. Acta, 354, 131\u2013139.","DOI":"10.1016\/j.cccn.2004.11.035"},{"key":"key\n\t\t\t\t20171012163544_SAWKAR-ET-AL-2002","doi-asserted-by":"crossref","unstructured":"Sawkar, A.R. , Cheng, W.C., Beutler, E., Wong, C.H., Balch, W.E., and Kelly, J.W. (2002) Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl. Acad. Sci. U. S. A.,99, 15428\u201315433.","DOI":"10.1073\/pnas.192582899"},{"key":"key\n\t\t\t\t20171012163544_SIDRANSKY-2005","doi-asserted-by":"crossref","unstructured":"Sidransky, E. (2005) Gaucher disease and parkinsonism. Mol. Genet Metab.,84, 302\u2013304.","DOI":"10.1016\/j.ymgme.2004.11.007"},{"key":"key\n\t\t\t\t20171012163544_SIMPSON-ET-AL-2004","doi-asserted-by":"crossref","unstructured":"Simpson, M.A. , Cross, H., Proukakis, C., Priestman, D.A., Neville, D.C., Reinkensmeier, G., Wang, H., Wiznitzer, M., Gurtz, K., Verganelaki, A., and others. (2004) Infantile\u2013onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase. Nat. Genet, 36, 1225\u20131229.","DOI":"10.1038\/ng1460"},{"key":"key\n\t\t\t\t20171012163544_SUZUKI-ET-AL-1998","doi-asserted-by":"crossref","unstructured":"Suzuki, K. , Proia, R.L., and Suzuki, K. (1998) Mouse models of human lysosomal diseases. Brain Pathol.,8, 195\u2013215.","DOI":"10.1111\/j.1750-3639.1998.tb00145.x"},{"key":"key\n\t\t\t\t20171012163544_DEL-ET-AL-2004","doi-asserted-by":"crossref","unstructured":"del Tessitore , A.P.M.M., Sano, R., Ma, Y., Mann, L., Ingrassia, A., Laywell, E.D., Steindler, D.A., Hendershot, L.M., and d\u2019Azzo, A. (2004) GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis. Mol. Cell, 15, 753\u2013766.","DOI":"10.1016\/j.molcel.2004.08.029"},{"key":"key\n\t\t\t\t20171012163544_TIERNEY-ET-AL-1995","doi-asserted-by":"crossref","unstructured":"Tierney, M. , Pottage, J., Kessler, H., Fischl, M., Richman, D., Merigan, T., Powderly, W., Smith, S., Karim, A., Sherman, J., and others. (1995) The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG, 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.,10, 549\u2013553.","DOI":"10.1097\/00042560-199510050-00008"},{"key":"key\n\t\t\t\t20171012163544_TIFFT-AND-PROIA-2000","doi-asserted-by":"crossref","unstructured":"Tifft, C.J. and Proia, R.L. (2000) Stemming the tide: glycosphingolipid synthesis inhibitors as therapy for storage diseases. Glycobiology, 10, 1249\u20131258.","DOI":"10.1093\/glycob\/10.12.1249"},{"key":"key\n\t\t\t\t20171012163544_TOMINAGA-ET-AL-2001","doi-asserted-by":"crossref","unstructured":"Tominaga, L. , Ogawa, Y., Taniguchi, M., Ohno, K., Matsuda, J., Oshima, A., Suzuki, Y., and Nanba, E. (2001) Galactonojirimycin derivatives restore mutant human beta-galactosidase activities expressed in fibroblasts from enzyme-deficient knockout mouse. Brain Dev.,23, 284\u2013287.","DOI":"10.1016\/S0387-7604(01)00216-9"},{"key":"key\n\t\t\t\t20171012163544_TROPAK-ET-AL-2004","doi-asserted-by":"crossref","unstructured":"Tropak, M.B. , Reid, S.P., Guiral, M., Withers, S.G., and Mahuran, D. (2004) Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff patients. J. Biol. Chem.,279, 13478\u201313487.","DOI":"10.1074\/jbc.M308523200"},{"key":"key\n\t\t\t\t20171012163544_TSUJI-ET-AL-2005","doi-asserted-by":"crossref","unstructured":"Tsuji, D. , Kuroki, A., Ishibashi, Y., Itakura, T., Kuwahara, J., Yamanaka, S., and Itoh, K. (2005) Specific induction of macrophage inflammatory protein 1-alpha in glial cells of Sandhoff disease model mice associated with accumulation of N-acetylhexosaminyl glycoconjugates. J. Neurochem.,92, 1497\u20131507.","DOI":"10.1111\/j.1471-4159.2005.02986.x"},{"key":"key\n\t\t\t\t20171012163544_VELLODI-2005","doi-asserted-by":"crossref","unstructured":"Vellodi, A. (2005) Lysosomal storage disorders. Br. J. Haematol.,128, 413\u2013431.","DOI":"10.1111\/j.1365-2141.2004.05293.x"},{"key":"key\n\t\t\t\t20171012163544_VUNNAM-AND-RADIN-1980","doi-asserted-by":"crossref","unstructured":"Vunnam, R.R. and Radin, N.S. (1980) Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain. Chem. Phys. Lipids, 26, 265\u2013278.","DOI":"10.1016\/0009-3084(80)90057-2"},{"key":"key\n\t\t\t\t20171012163544_YAM-ET-AL-2005","doi-asserted-by":"crossref","unstructured":"Yam, G.H. , Zuber, C., and Roth, J. (2005) A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder. FASEB J.,19, 12\u201318.","DOI":"10.1096\/fj.04-2375com"},{"key":"key\n\t\t\t\t20171012163544_YAMASHITA-ET-AL-1999","doi-asserted-by":"crossref","unstructured":"Yamashita, T. , Wada, R., Sasaki, T., Deng, C.X., Bierfreund, U., Sandhoff, K., and Proia, R.L. (1999) A vital role for glycosphingolipid synthesis during development and differentiation. Proc. Natl. Acad. Sci. U. S. A.,96, 9142\u20139147.","DOI":"10.1073\/pnas.96.16.9142"},{"key":"key\n\t\t\t\t20171012163544_ZERVAS-ET-AL-2001","doi-asserted-by":"crossref","unstructured":"Zervas, M. , Somers, K.L., Thrall, M.A., and Walkley, S.U. (2001) Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr. Biol.,11, 1283\u20131287.","DOI":"10.1016\/S0960-9822(01)00396-7"},{"key":"key\n\t\t\t\t20171012163544_ZIMRAN-1997","unstructured":"Zimran, A. (1997) Gaucher\u2019s disease. Bailliere\u2019s clinical Haematology. In International Practice and Research. Bailiere Tindall, London, 10, 621\u2013846."},{"key":"key\n\t\t\t\t20171012163544_ZITZMANN-ET-AL-1999","doi-asserted-by":"crossref","unstructured":"Zitzmann, N. , Mehta, A.S., Carrouee, S., Butters, T.D., Platt, F.M., McCauley, J., Blumberg, B.S., Dwek, R.A., and Block, T.M. (1999) Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. Proc. Natl. Acad. Sci. U. S. A.,96, 11878\u201311882.","DOI":"10.1073\/pnas.96.21.11878"}],"container-title":["Glycobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/glycob\/article-pdf\/15\/10\/43R\/2040367\/cwi076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,11]],"date-time":"2021-07-11T02:22:44Z","timestamp":1625970164000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/glycob\/article\/15\/10\/43R\/693656\/Imino-sugar-inhibitors-for-treating-the-lysosomal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,18]]},"references-count":82,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2005,5,18]]},"published-print":{"date-parts":[[2005,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/glycob\/cwi076","relation":{},"ISSN":["1460-2423","0959-6658"],"issn-type":[{"value":"1460-2423","type":"electronic"},{"value":"0959-6658","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,10]]},"published":{"date-parts":[[2005,5,18]]}}}